Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.

Koschel S, Murphy DG, Hofman MS, Wong LM.

Curr Opin Urol. 2019 Nov;29(6):569-577. doi: 10.1097/MOU.0000000000000677.

PMID:
31567440
2.

Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.

Koschel SG, Wong LM, Heinze S, Zargar H.

Eur Urol. 2019 Nov;76(5):704-705. doi: 10.1016/j.eururo.2019.05.020. Epub 2019 May 28. No abstract available.

PMID:
31146898
3.

Long-term oncological outcomes of patients with paratesticular sarcoma.

Goldberg H, Wong LM, Dickson B, Catton C, Yap SA, Alkasab T, Evans A, van der Kwast T, Jewett MAS, Hamilton RJ.

BJU Int. 2019 Nov;124(5):801-810. doi: 10.1111/bju.14775. Epub 2019 May 6.

PMID:
31001920
4.

Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.

Kam J, Yuminaga Y, Krelle M, Gavin D, Koschel S, Aluwihare K, Sutherland T, Skinner S, Brennan J, Wong LM, Louie-Johnsun M.

BJU Int. 2019 Aug;124(2):297-301. doi: 10.1111/bju.14696. Epub 2019 Feb 25.

PMID:
30714285
5.

Comparing infective complications from transrectal ultrasound guided prostate biopsy following transition to single dose oral ciprofloxacin prophylaxis.

Farag M, Riddell S, Daffy J, Wong LM.

Investig Clin Urol. 2019 Jan;60(1):54-60. doi: 10.4111/icu.2019.60.1.54. Epub 2018 Dec 12.

6.

Secondary spindle cell sarcoma following external beam radiotherapy for prostate cancer: a rare but devastating complication.

Farag M, Ta A, Shankar S, Wong LM.

BMJ Case Rep. 2018 Jul 11;2018. pii: bcr-2018-225295. doi: 10.1136/bcr-2018-225295.

PMID:
30002213
7.

New Histopathological & Genetic Features to Improve Active Surveillance Selection for Low-Risk Prostate Cancer.

Chu K, Corcoran N, Norden S, Wong LM.

Anticancer Agents Med Chem. 2018;18(7):951-957. doi: 10.2174/1871520617666171114105846.

PMID:
29141559
8.

Hospital volume and perioperative outcomes for radical cystectomy: a population study.

Udovicich C, Perera M, Huq M, Wong LM, Lenaghan D.

BJU Int. 2017 May;119 Suppl 5:26-32. doi: 10.1111/bju.13827.

9.

Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.

Wong LM, Tang V, Peters J, Costello A, Corcoran N.

BJU Int. 2016 Apr;117 Suppl 4:82-7. doi: 10.1111/bju.13460.

10.

Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.

Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M, Shaw M, Chander S, Pham D, Lawrentschuk N, Wong LM, Goad J, Foroudi F.

Radiother Oncol. 2016 Mar;118(3):540-6. doi: 10.1016/j.radonc.2016.01.027. Epub 2016 Feb 9.

PMID:
26873790
11.

An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.

Komisarenko M, Wong LM, Richard PO, Timilshina N, Toi A, Evans A, Zlotta A, Kulkarni G, Hamilton R, Fleshner N, Finelli A.

J Urol. 2016 Feb;195(2):307-12. doi: 10.1016/j.juro.2015.09.081. Epub 2015 Sep 28.

PMID:
26417646
12.

Renal Embolization and Urothelial Sclerotherapy for Recurrent Obstructive Urosepsis and Intractable Haematuria from Upper Tract Urothelial Carcinoma.

Brown N, Olayos E, Elmer S, Wong LM, Brooks DM, Jhamb A.

Cardiovasc Intervent Radiol. 2016 Mar;39(3):467-71. doi: 10.1007/s00270-015-1184-2. Epub 2015 Jul 24.

PMID:
26206598
13.

Active surveillance in patients with a PSA >10 ng/mL.

Toren P, Wong LM, Timilshina N, Alibhai S, Trachtenberg J, Fleshner N, Finelli A.

Can Urol Assoc J. 2014 Sep;8(9-10):E702-7. doi: 10.5489/cuaj.2121.

14.

Unusual presentation of advanced prostate cancer masquerading as metastatic and obstructing rectosigmoid cancer.

Chang MD, Davidson AJ, Sutherland T, De Fontgalland D, Johnson D, Wong LM.

ANZ J Surg. 2017 May;87(5):417-419. doi: 10.1111/ans.12917. Epub 2014 Nov 12. No abstract available.

PMID:
25388794
15.

Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.

Wong LM, Toi A, Van der Kwast T, Trottier G, Alibhai SM, Timilshina N, Evans A, Zlotta A, Fleshner N, Finelli A.

J Urol. 2014 Oct;192(4):1088-93. doi: 10.1016/j.juro.2014.04.010. Epub 2014 Apr 15.

PMID:
24742593
16.

Prospective evaluation of irrigation fluid absorption during pure transurethral bipolar plasma vaporisation of the prostate using expired-breath ethanol measurements.

Hermanns T, Fankhauser CD, Hefermehl LJ, Kranzbühler B, Wong LM, Capol JC, Zimmermann M, Sulser T, Müller A.

BJU Int. 2013 Sep;112(5):647-54. doi: 10.1111/bju.12170. Epub 2013 Jun 14.

17.

Urologists in cyberspace: A review of the quality of health information from American urologists' websites using three validated tools.

Wong LM, Yan H, Margel D, Fleshner NE.

Can Urol Assoc J. 2013 Mar-Apr;7(3-4):100-7. doi: 10.5489/cuaj.501.

18.

A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.

Wong LM, Alibhai SM, Trottier G, Timilshina N, Van der Kwast T, Zlotta A, Lawrentschuk N, Kulkarni G, Hamilton R, Ferrara S, Margel D, Trachtenberg J, Jewett MA, Toi A, Evans A, Fleshner NE, Finelli A.

Eur Urol. 2014 Sep;66(3):406-13. doi: 10.1016/j.eururo.2013.04.038. Epub 2013 May 2.

PMID:
23664820
19.

Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a time-dependent covariate reanalysis.

Wong LM, Fleshner N, Finelli A.

Eur Urol. 2013 Aug;64(2):343. doi: 10.1016/j.eururo.2013.04.018. Epub 2013 Apr 18. No abstract available.

PMID:
23622776
20.

The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer.

Johnston R, Wong LM, Warren A, Shah N, Neal D.

ANZ J Surg. 2013 Apr;83(4):234-8. doi: 10.1111/ans.12094. Epub 2013 Mar 6.

PMID:
23463964

Supplemental Content

Loading ...
Support Center